All In Biotech

NDA 020272 · Janssen Pharms

Risperdal

Risperidone · Oral · Atypical Antipsychotic

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Dec 29, 1993

Approved uses

10

Original approval plus efficacy supplements

Registered trials

514

127 Phase 3, 14 recruiting

FAERS reports

121,516

83,453 serious, 9,507 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Oct 23, 2026.

RISPERDAL is an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) 1.1 Schizophrenia RISPERDAL (risperidone) is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1) ] . 1.2 Bipolar Mania Monotherapy RISPERDAL is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Clinical Studies (14.2) ] . Adjunctive Therapy RISPERDAL adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Clinical Studies (14.3) ] . 1.3 Irritability Associated with Autistic Disorder RISPERDAL is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) [see Clinical Studies (14.4) ] .

Mechanism: The mechanism of action of risperidone in schizophrenia is unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology (12.3) ] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone [see Clinical Pharmacology (12.1) ] .

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • RISPERDAL · RISPERIDONE 0.25MG · TABLET, ORAL · Prescription · TE AB
  • RISPERDAL · RISPERIDONE 4MG · TABLET, ORAL · Prescription · TE AB
  • RISPERDAL · RISPERIDONE 2MG · TABLET, ORAL · Prescription · TE AB
  • RISPERDAL · RISPERIDONE 0.5MG · TABLET, ORAL · Prescription · TE AB
  • RISPERDAL · RISPERIDONE 5MG · TABLET, ORAL · Discontinued
  • RISPERDAL · RISPERIDONE 3MG · TABLET, ORAL · Prescription · TE AB
  • RISPERDAL · RISPERIDONE 1MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Risperidone" as an intervention, any sponsor and status, largest first.

All 514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gynaecomastia24,464
  • off label use12,012
  • abnormal weight gain9,410
  • weight increased8,935
  • drug ineffective7,389
  • product use in unapproved indication5,942
  • emotional disorder5,911
  • injury4,618
  • drug interaction4,510
  • hyperprolactinaemia4,424
  • somnolence4,365
  • galactorrhoea3,705

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,082
20052,052
20062,349
20072,212
20082,285
20093,901
20103,696
20113,714
20123,761
20133,058
20144,161
201512,643
201613,493
201713,038
20186,712
20197,593
20206,046
20214,893
20225,329
20234,918
20245,290
20254,848
20263,441

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Risperdal (Risperidone)

2024 spending

$3.6M

Beneficiaries

954

6,767 claims

Per beneficiary

$3,817

$7.29 per unit

View as table
YearSpending
2020$11,292,438
2021$9,168,124
2022$4,387,669
2023$4,170,926
2024$3,641,519

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,258 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.